Type I collagen metabolites as tumor markers in patients with lung carcinoma

Cancer

Volumn 85, Issue 9, 1999, Pages 1951-1957

  Kobayashi, Tetsu ^a   Gabazza, Esteban C ^a   Taguchi, Osamu ^a   Risteli, Juha ^c   Risteli, Leila ^c   Kobayashi, Hiroyasu ^a   Yasui, Hiroki ^a   Yuda, Hisamichi ^a   Sakai, Takashi ^b   Kaneda, Masanori ^b   Adachi, Yukihiko ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Lung carcinoma; Metastasis; Prognosis; Type I collagen

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; COLLAGEN TYPE 1; D DIMER; ETOPOSIDE; GLYCOPROTEIN; MITOMYCIN C; NEURON SPECIFIC ENOLASE; PROCOLLAGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; VINDESINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CASE-CONTROL STUDIES; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 0033134946     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990501)85:9<1951::AID-CNCR11>3.0.CO;2-H     Document Type: Article

References (25)

1. Liotta LA. Tumor invasion and metastasis: role of the extracellular matrix. Cancer Res 1986;46:1-7.
2. Terranova PV, Hujanen ES, Martin G. Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 1986;77:311-6.
3. Risteli J, Risteli L. Analysing connective tissue metabolites in human serum: biochemical, physiological and methological aspects. J Hepatol 1995;22:77-81.
4. Risteli L, Kauppila A, Makila UM, Risteli J. Aminoterminal propeptide of type III procollagen in serum: an indicator of clinical behavior of advanced ovarian carcinoma. Int J Cancer 1988;41:409-14.
5. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Tsutsui K, et al. Coagulation-fibrinolysis system and markers of collagen metabolism in lung cancer. Cancer 1992;70: 2631-6.
6. Gabazza EC, Taguchi O, Yoshida M, Yamakami T, Kobayashi H, Ibata H, et al. Collagen markers during anticancer therapy for lung cancer. Oncol Rep 1995:3;147-50.
7. Tahtela R, Tholix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anti-cancer Res 1996;16:2289-94.
8. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL. Collagen cross-link metabolites iin urine as markers of bone metastases in prostatic carcinoma. J Urol 1994;151:909-13.
9. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-41.
10. Zhu G, Risteli L, Makinen M, Risteli J, Kauppila A, Stenback F. Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms. Cancer 1995;75:1010-7.
11. Blomqvist C, Risteli L, Risteli J, Virkkunnen PP, Sarna S, Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastasis from breast carcinoma. Br J Cancer 1996; 73:1074-9.
12. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225.
13. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
14. Erdreich LS, Lee ET. Use of relative operating characteristic analysis in epidemiology. Am J Epidemiol 1981;114: 649-62.
15. Bateman JF, Lamande SR, Ramshaw JAM. Collagen superfamily. In: Comper WD. Extracellular matrix. Tokyo, Japan: Harwood Academic Publishers; 1996:22-67.
16. Jukkola A, Tahtela R, Tholix E, Vuorinen K, Blanco G, Risteli L, et al. Aggressive breast cancer leads to discrepant serum levelsof the type I procollagen propeptides PINP and PICP. Cancer Res 1997;57:5517-20.
17. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284:67-8.
18. Biswas C. Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun 1982; 109:1026-34.
19. Kwaan HC, Keer HN. Fibrinolysis and cancer. Semin Thromb Hemost 1990;16:230-5.
20. Grondhal-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
21. Gabazza EC, Taguchi O, Yoshida M, Yamakami T, Kobayashi H, Ibata H, et al. Neutrophil activation and collagen metabolism in lung cancer. Clin Chim Acta 1995;236:101-8.
22. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997;52:563-5.
23. Taguchi O, Gabazza EC, Yoshida M, Yamakami T, Kobayashi H, Shima T. High plasma level of plasmina2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clin Chim Acta 1996;244:69-81.
24. Mizushima Y, Hirata H, Izumi S, Hoshino K, Konishi K, Morikage T. Clinical significance of the number of positive tumor marker in assisting the diagnosis of lung cancer with multiple tumor marker assays. Oncology 1990;47:43-8.
25. Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 1997;76:760-4.